Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-19 01:21 CEST (UTC+2h)
ElMaestro
Hero

Denmark,
2017-12-16 12:31

Posting: # 18064
Views: 998
 

 What's the current situation regarding chiral assays? [Bioanalytics]

Hi all,

what is the current regulatory sentiment towards the need for chiral assays?

My impression is, given the EU guideline wording in 4.1.5 and the current practice that I have seen that regulators are not really enforcing the guideline the way it is written but occasionally they just happen to be.
I cannot see a pattern in the practice. If someone asks me when a chiral assay is truly necessary (guideline wording apart) then I will have to draw a blank.

Anyone out there able to describe how the guideline wording translates into assessor practice in plain words?

Many thanks and have a good day.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
Helmut
Hero
avatar
Homepage
Vienna, Austria,
2017-12-16 13:23

@ ElMaestro
Posting: # 18065
Views: 862
 

 The “backdoor”

Hi ElMaestro,

» what is the current regulatory sentiment towards the need for chiral assays?

Duno. Agree with your other statements. See also this post. At a conference in 2014 another regulator told me that this paragraph is a kind of “backdoor”:

If we don’t like [sic!] the study and find no other reason to reject it, we can use the backdoor…

Note also that all product-specific guidances published so far don’t recommend a chiral assay.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,384 posts in 3,905 threads, 1,172 registered users;
online 13 (1 registered, 12 guests [including 11 identified bots]).

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed